Undated Infinition Sails!

# **Comprehensive Practical Information Focused on Patient Care**

- Gather information on emerging treatment trends
- Interact with a worldrenowned faculty
- Design your own learning experience with a multidisciplinary program



September 6-9, 2007

Hilton San Francisco • San Francisco, CA









Earn 23+ CME's

www.oncologycongress.com/attend



## 2007 Highlights

#### TARGET AUDIENCE

- Medical Oncologists
- Hematologists/Oncologists
- Surgical Oncologists
- Radiation Oncologists
- Hematologists
- Oncology Nurse Practitioners
- Oncology Nurses
- Oncology Pharmacists
- Physician Assistants
- Psycho-Social Oncologists
- Allied Oncology Healthcare Professionals

#### PROGRAM **OVERVIEW**

Developed for the US-based practicing oncologist, the Oncology Congress leads in delivering knowledge, tools, and insight into the best practices that leaders in cancer prevention, diagnosis, and treatment need to improve patient care. An exclusive, capacity-controlled environment featuring the top names in oncology stimulates peer-to-peer dialogue by providing a meeting large enough for networking and small enough for debate.

### **Learning Objectives**

At the conclusion of the Oncology Congress, participants will be better able to:

- Assess the impact of recent research findings in cancer diagnosis and treatment on clinical practice
- Evaluate and integrate new therapies and treatment regimens into clinical practice
- Determine the most efficacious strategies for the treatment of the following cancers: bladder, breast, cervical, colon, head & neck, lung, ovarian, pancreatic, prostate, testicular, sarcoma, leukemia, lymphoma, melanoma, and myeloma, in addition to supportive care and survivorship issues
- Assess optimal radiation/chemoradiation treatment strategies
- Review methods to minimize symptoms related to treatment side effects and complications of treatment
- Review methods of managing psychosocial and quality-of-life issues experienced in cancer patients
- Better understand attitudes, concerns and needs of cancer survivors
- Understand innovations in targeted, local and systemic therapies
- Assemble a network of professional colleagues with common interests to solve problems, share experiences, and provide mutual professional support



- "Oncology Congress covers common, day-to-day topics the problems we confront on a daily basis. They covered nuts and bolts that I can use in my everyday practice."
  - Rakesh Mehta, MD
     Department of Veterans Affairs Medical Center Castle Point, NY

### DESIGN YOUR OWN LEARNING EXPERIENCE

Our multidisciplinary program allows you to focus on the areas most important to your practice. You can devote your time to one therapeutic area, or focus on several topics – the choice is yours. Consult the listing below to design an optimal learning experience that meets your specific educational goals.

В	Breast Cancer
GI	Gastrointestinal Malignancies
GY	Gynecologic Malignancies
Н	Hematologic Malignancies
HN	Head and Neck Cancer
L	Lung Cancer
M	Melanoma
PM	Practice Management
R0	Radiation Oncology
S	Sarcoma
SC	Supportive Care
SV	Survivorship
U	Urologic Malignancies

#### WAUN KI HONG, MD -FOUNDING CHAIRMAN'S DINNER RECEPTION

#### Saturday • September 8, 2007

6:30 pm - 10:00 pm

This fundraising event, named for Oncology Congress' founding chair, honors and celebrates the lives of those who have been touched by cancer and those who treat and care for them. A wonderful evening, featuring a cocktail party, dinner, silent auction and entertainment. Seating is limited so reserve your tickets early. Tickets for conference attendees and guests are \$99.

Sponsorship opportunities are available. Please contact Jeanne Brandt at 203-840-5460 or email jbrandt@reedmeded.com.



#### Friday • September 7, 2007

7:00 am - 8:00 am

#### Sunday • September 9, 2007

7:00 am - 8:00 am

#### **Discussion Leaders:**

Michael J. Fisch, MD, MPH The University of Texas M. D. Anderson Cancer Center

Caroline Carney-Doebbeling, MD, MSc Indiana University Cancer Center

Schwartz Center Rounds are one-hour meetings that offer health care professionals the opportunity to discuss: issues about time pressures; the challenge of breaking bad news; the need to keep hope alive; the balance of sympathy and empathy and keeping personal boundaries, as well as dealing with both the patient's and their own emotional reactions.

- "The focus is on emotional and social issues that arise in caring for patients. So we look at how our own reactions as doctors affect the patient. In addition, these rounds are more inwardly directed, 'mindful,' as opposed to having a problem-solving and information-exchange orientation."
  - Michael J. Fisch, MD, MPH
     The University of Texas M. D. Anderson Cancer Center

The program is named after healthcare attorney Kenneth Schwartz, who died at the age of 40, less than a year after he was diagnosed with advanced lung cancer. Appreciative of the medical care he received, Schwartz said what meant most to him was the empathy and compassion from providers who took the time to answer his questions, just sat with him, and always made him feel like they were committed to making sure his quality of life was the best it could be.

- "Looking back, I realize that in a high-volume setting, the high-pressure atmosphere tends to stifle a caregiver's inherent compassion and humanity. But the briefest pause in the frenetic pace can bring out the best in a caregiver and do much for a terrified patient."
  - Kenneth Schwartz, The Boston Globe Magazine

Rounds are open to all cancer care team members, but will be limited to 40 participants to help facilitate the ability to interact. Pre-registration is required to ensure your seat.

## 2007 Highlights

## FACULTY SCHEDULED OFFICE HOURS

Didn't get the chance to ask one of the faculty members a question? Would like to talk about a particular patient issue? Just want to stop by and shake hands? "Office Hours" allow you to interact with the faculty in a relaxed and comfortable setting. This program received many accolades at the 2006 conference.

#### Office Hours with Faculty (tentative)

#### Friday • September 7th

10:30 am - 11:30 am

Everett E. Vokes, MD Martin Tallman, MD Cary A. Presant, MD

3:00 pm - 4:00 pm

Paul F. Engstrom, MD Alan P. Venook, MD Patrick J. Loehrer, Sr., MD John T. Soper, MD

#### Saturday · September 8th

10:00 am - 11:00 am

Kenneth C. Anderson, MD George W. Sledge, Jr., MD David H. Johnson, MD

3:30 pm - 4:30 pm

Hyman B. Muss, MD Theodore T. DeWeese, MD Otis W. Brawley, MD Laurence H. Baker, DO

### CLINICAL CASE STUDIES

Participants work in small groups to identify approaches to resolve the case issue. These sessions are led by an expert but are more focused on the sharing of information and gaining insights from the group. Each challenging case study is limited to 20 attendees, so you are encouraged to register early if you plan on attending.

#### **Case Studies**

#### Friday • September 7th

10:45 am - 11:15 am

CS201: Case Study in Urologic Malignancies

CS202: Case Study in Hematologic Malignancies

CS203: Case Study in Neuroendocrine Cancer/Carcinoid Tumor

Paul F. Engstrom, MD Fox Chase Cancer Center

CS204: Case Study in Central Nervous System Tumors

#### Saturday · September 8th

3:00 pm - 3:45 pm

CS301: Case Study in Breast Cancer: Discussion Of The Added Value Of Adjuvant Chemotherapy In An Older Patient (I.E. 70 Years) With Node-Positive, Hormone Receptor Positive Early Breast Cancer Hyman B. Muss, MD

Vermont Cancer Center
CS302: Case Study in Gynecologic Malignancies

Bradley J. Monk, MD
University of California Irvine Medical Center

CS303: Case Study in Central Nervous System Tumors

CS304: Case Study in Pancreatic Cancer

#### ACCREDITATION STATEMENT

Physicians – This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME) and Reed Medical Education. The EOCME is accredited by the ACCME to provide continuing medical education (CME) for physicians. The EOCME designates this continuing medical education activity for a maximum of 23.75 AMA PRA Category 1 Credit(s).™ Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses - The American Nurses Credentialing Center accepts Continuing Medical Education (CME) for certification renewal. One CME = 1.0 Contact Hours.

Faculty Disclosure – It is Reed Medical Education's policy that faculty participating in any of their CME activities disclose to the participants any real or apparent conflict of interest related to the content of their presentation. Each faculty member has completed and signed a conflict of interest statement. Relationships will be disclosed to the audience at the time of the activity.

## Advisory Board

**CHAIRPERSON** 



Patrick J. Loehrer Sr., MD Indiana University Cancer Center/ Indiana University School of Medicine

Co-CHAIRS



Paul F. Engstrom, MD Fox Chase Cancer Center



Cary A. Presant, MD USC Keck School of Medicine/ Wilshire Oncology Medical Group, Inc.

FOUNDING CHAIR



Waun Ki Hong, MD
The University of Texas
M. D. Anderson Cancer Center

**ADVISORS** 



Kenneth C. Anderson, MD Dana-Farber Cancer Institute/ Harvard Medical School



**David H. Johnson, MD** Vanderbilt-Ingram Cancer Center/ Vanderbilt University



Laurence H. Baker, DO Southwest Oncology Group/ University of Michigan Comprehensive Cancer Center



Theodore S. Lawrence, MD, PhD University of Michigan Comprehensive Cancer Center/ University of Michigan Health System



Otis W. Brawley, MD Georgia Cancer Center for Excellence/Winship Cancer Institute/Emory University



Hyman B. Muss, MD Vermont Cancer Center/Fletcher Allen Healthcare/University of Vermont



Theodore L. DeWeese, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins



George W. Sledge, Jr., MD Indiana University Cancer Center/ Indiana University School of Medicine



Michael J. Fisch, MD, MPH The University of Texas M. D. Anderson Cancer Center



**John T. Soper, MD** University of North Carolina School of Medicine



Frank G. Haluska, MD, PhD Tufts-New England Medical Cancer Center/Tufts University School of Medicine



Martin S. Tallman, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University/Northwestern University Medical School



Sandra J. Horning, MD Stanford Comprehensive Cancer Center/Stanford University School of Medicine



Alan P. Venook, MD UCSF Comprehensive Cancer Center



Catherine Hydzik, RN, MS, AOCN Memorial Sloan-Kettering Cancer Center



**Everett E. Vokes, MD**The University of Chicago Hospitals

## Faculty

Janet L. Abrahm, MD

Dana-Farber Cancer Institute

Anthony L. Back, MD

Seattle Cancer Care Alliance University of Washington

Joseph S. Bailes, MD

American Society of Clinical Oncology

Dean F. Bajorin, MD

Memorial Sloan-Kettering Cancer Center

Charles M. Balch, MD

Johns Hopkins Medical Institutions

**Nabeel Bardeesy, PhD** 

Massachusetts General Hospital Cancer Center

**Edgar Ben-Josef, MD** 

University of Michigan Health System

William I. Bensinger, MD

University of Washington Fred Hutchinson Cancer Reseach Center

Jonathan S. Berek, MD, MMS

Stanford University School of Medicine

**Emily K. Bergsland, MD** 

**UCSF Comprehensive Cancer Center** 

Rodger L. Bick, MD, PhD

University of Texas Southwestern Medical Center

J. Sybil Biermann, MD

University of Michigan Cancer Center

Linda D. Bosserman, MD

Wilshire Oncology Medical Group, Inc.

Rebecca L. Brown, MD

The University of Chicago Hospitals

Robert A. Buckman, MB, PhD

**Princess Margaret Hospital** 

Harold J. Burstein, MD, PhD

Harvard Medical School

Aman U. Buzdar, MD

The University of Texas M. D. Anderson Cancer Center

Caroline Carney-Doebbeling MD, MSc

Indiana University Cancer Center

Peter R. Carroll, MD

**UCSF Comprehensive Cancer Center** 

Victor T. Chang, MD

VA New Jersey Health Care System

Paul B. Chapman, MD

Memorial Sloan-Kettering Cancer Center

Herbert Chen, MD

University of Wisconsin

Ezra EW Cohen, MD

University of Chicago Hospitals

Megan Cole, MA

University of Texas Houston Health Science Center

A. Dimitrios Colevas, MD

Stanford University Medical Center

William L. Dahut, MD

**National Cancer Institute** 

Nancy A. Dawson, MD

Lombardi Comprehensive Cancer Center Georgetown University

Samuel R. Denmeade, MD

Johns Hopkins University

Dan Douer, MD

USC/Norris Comprehensive Cancer Center

Fred N. Ekery, MD

US Oncology, Inc.

Douglas B. Evans, MD

The University of Texas

M. D. Anderson Cancer Center

Robert A. Figlin, MD

City of Hope National Medical Center

Randy D. Gascoyne, MD, FRCPC

The University of British Columbia

**Timothy Gilligan, MD** 

Cleveland Clinic

Taussig Cancer Clinic

Michael K. Gould, MD, MS

VA Palo Alto Health Care System

William J. Gradishar, MD

Robert H. Lurie Cancer Center Northwestern University

**Axel Grothey, MD** 

Mayo Clinic College of Medicine

Paul M. Harari, MD

University of Wisconsin

Carone Comprehensive Cancer Center

Dawn G. Holcombe, MBA, FACMPE

Connecticut Oncology Association

Richard T. Hoppe, MD

Stanford University Medical Center

Bradley S. Kahl, MD

University of Wisconsin School of Medicine and Public Health

Michael O. Koch, MD

Indiana University Cancer Center

Michael R. Kuettel, MD, PhD

Roswell Park Cancer Institute

Corey J. Langer, MD

Fox Chase Cancer Center

David H. Lawson, MD

**Emory University** 

Winship Cancer Institute

Quynh-Thu Le, MD

Stanford Comprehensive Cancer Center

Susan A. Leigh, RN, BSN

National Coalition for Cancer Survivorship

David G. Maloney, MD, PhD

Fred Hutchinson Cancer Research Center

Michael J. Mauro, MD

Oregon Health and Science University

Bradley J. Monk, MD

University of California Irvine Medical Center

Mary F. Mulcahy, MD

Northwestern University

David G. Mutch, MD

Washington University School of Medicine

Kevin C. Oeffinger, MD

Memorial Sloan-Kettering Cancer Center

#### Mark D. Pegram, MD

UCLA Center for Health Sciences

#### Edith A. Perez, MD

Mayo Clinic Jacksonville

#### Philip A. Philip, MD, PhD

Barbara Ann Karmanos Cancer Institute Wayne State University

#### Joe B. (Bill) Putnam, Jr., MD

Vanderbilt-Ingram Cancer Center

#### Peter Ravdin, MD, PhD

The University of Texas M. D. Anderson Cancer Center

#### Gregory J. Riely, MD

Memorial Sloan-Kettering Cancer Center

#### Les L. Robison, PhD

St. Jude Children's Research Hospital

#### David I. Rosenthal, MD

The University of Texas M. D. Anderson Cancer Center

#### Merrick I. Ross, MD

The University of Texas M. D. Anderson Cancer Center

#### Julia H. Rowland, PhD

**National Cancer Institute** 

#### Hope S. Rugo, MD

**UCSF Comprehensive Cancer Center** 

#### Howard M. Sandler, MD

University of Michigan

#### Charles A. Schiffer, MD

Barbara Ann Karmanos Cancer Institute Wayne State University

#### **Ayalew Tefferi, MD**

Mayo Clinic Rochester

#### Joel E. Tepper, MD

**UNC Lineberger Comprehensive** Cancer Center

#### James L. Wade III, MD

Cancer Care Specialists of Central Illinois

#### Robert S. Warren, MD

**UCSF Comprehensive Cancer Center** 

#### H. Jack West, MD

**Swedish Cancer Institute** 

#### William G. Wierda, MD, PhD

The University of Texas M. D. Anderson Cancer Center

#### Timothy G. Wilson, MD

City of Hope National Medical Center

For a full list of faculty, visit www.oncologycongress.com/attend



- "Oncology Congress provides a nice, concise summary of recent updates, best practices and the latest data for radiation, medical and surgical oncologists. I'm from a combined group, and it gives me the broader perspective I need. The presentations are focused on very practical concerns of community-based oncologists."
  - Gregg E. Franklin, MD, PhD Radiation Oncologist New Mexico Cancer Center Albuquerque, New Mexico
- "What I particularly liked about Oncology Congress was the ability to interact easily with speakers, many of whom were thought leaders. People who are on the forefront of either research, experimental or investigational therapy, whose ideas make a big difference in the clinical trials."
  - Kesav Nair, MD

Medical Oncologist Norwalk Medical Group Norwalk, Connecticut

- "Oncology Congress concentrates on tightly melded presentations of what's new. Whether it's epidemiology, workup, or treatment, they're trying to teach. And this is very well done."
  - Thomas Herskovic, MD Radiation Oncologist St. Joseph's Hospital and Medical Center Paterson, New Jersey

## Plenary Sessions

### FRIDAY SEPTEMBER 7th

11:35 am - 12:20 pm

Session P201

Personal Burdens and Rewards of Being a Cancer Physician





Robert A. Buckman, MB, PhD/Megan Cole, MA

The job of being an oncologist carries considerable burdens (as well as rewards). The personal burdens can best be considered under three main headings: 1. DECISION-MAKING: Perhaps the most obvious source of stress is the making of everyday management decisions for each patient. This is itself made worse by (a) time constraints (b) the high possibility of therapeutic intervention being unsuccessful ("therapeutic failure") and (c) the emotional overtones (for the patient and the physician) amplified by (a) and (b). 2. EMOTIONAL BURDENS: Even when management decisions are not a problem, dealing with the emotional component of the patient-physician interaction is very demanding. Specific and practical communication techniques are required in order to identify and deal with emotions (which may be in the 'background' and not overtly expressed). 3. LIVING-WORKING BALANCE: The physician needs to be aware of the potential danger of burn-out, and needs to regard life outside the hospital as an essential adjunct and support to her or his ability to continue functioning as a physician. Outside interests are an essential part of the oncologist's ability to maintain some degree of equanimity. Without them, the physician will not be a "renewable resource."

This presentation will concentrate on these three main areas and present further analysis and together with practical suggestions.

4:00 pm - 5:00 pm

Session P202

**Lancet Oncology Plenary Lecture** 

Visit www.oncologycongress.com for updated information.

### SATURDAY SEPTEMBER 8th

11:00 am - 12:00 pm

Session P301







David H. Johnson, MD/Sandra J. Horning, MD

Oncologists are people too. They also get cancer. Does it make them a better physician? This session offers some eye-opening insights, through a unique dual perspective as physician and patient, of both sides of the medical divide.

Dr. Sandra Horning and Dr. David Johnson are both oncologists. Both of them are cancer survivors – and both past presidents of ASCO, the first to lead the society as cancer survivors.

Find out what new perspectives they gained on their journey as cancer patients: what surprised them most, what important lessons were learned from their experience, how has their patient care changed as a result of having cancer.

Dr. Horning is Professor of Medicine (Oncology and Blood and Marrow Transplantation) at Stanford University School of Medicine. She is Chair of the Lymphoma Committee of the Eastern Cooperative Oncology Group (ECOG) and Principal Investigator for phase II and III clinical trials in Hodgkin's disease and lymphoma. Her research interests include novel therapies, clinicopathologic correlative studies, post-transplantation lymphoproliferative disorders and complications of therapy.

Dr. Johnson is a medical oncologist who specializes in lung cancer, breast cancer, and experimental therapeutics, (developing and testing new anti-cancer treatment therapies). His clinical research efforts focus on the management of thoracic malignancies and the biology and treatment of breast cancers.

2:35 pm - 3:30 pm

Session P302

Cancer and the Oncologist in the 21st Century

David H. Johnson, MD



Why did we become physicians and oncologists? What are the daily challenges that make us forget our real purpose? How do we get past these challenges and get on with putting our patients first?

Dr. Johnson will address top of mind issues that dominate the future of the practicing oncologist. The demands imposed by reimbursement changes, regulatory burdens, ensuring quality cancer care in all practice settings, reimbursement tied to performance, and the basic integrity of oncology.

## Pre-Conference Workshops



### THURSDAY SEPTEMBER 6th

### Focus on Practice Management

Moderator: Cary A. Presant, MD

1:00 pm - 4:00 pm

Today's healthcare policy and practices demand greater efficiency, increased productivity, stricter accountability, tighter security, and rigorous cost containment. Never before have you had to put so much attention on countless issues that can make or break your practice all while continuing your patients' access to quality care.

#### Who should attend:

- Oncologists
- Practice Owners
- Directors
- Managers
- Administrators

#### Session PM101

How Can You Be Time Efficient and Address Problems?

Linda D. Bosserman, MD

Session PM102

Oncology in the 21st Century: Proving Your Worth

Dawn G. Holcombe, MBA, FACMPE

Session PM103

**Optimal Size of Practices** 

Fred N. Ekery, MD

Session PM104

**Clinical Trials** 

James L. Wade, III, MD

Session PM105

Legislative Update

Joseph S. Bailes, MD

#### Focus on Survivorship

Moderator: Paul F. Engstrom, MD

1:00 pm - 4:00 pm

Major advances in cancer prevention, early detection and treatment have resulted in longer survival. As of January 2003, it is estimated that there are 10.5 million cancer survivors in the U.S., representing approximately 3.6% of the population. However, surviving cancer can leave a host of problems in its wake. Cancer survivors are at greater risk for recurrence and for developing second cancers, due to the effects of treatment, continued lifestyle behaviors, underlying genetics, or risk factors that contributed to the first cancer.

This workshop will educate professionals who deal with cancer survivors about issues and practices critical to the optimal well-being of their patients.

#### Who should attend:

- Oncologists
- Primary Care Physicians
- Nurses
- Physician Assistants
- Social Workers
- Case Managers

Session SV101

**Historical Development** 

Julia H. Rowland, PhD

Session SV102

**Patient Perspective** 

Susan A. Leigh, RN, BSN

Session SV103

Primary Care Physician Perspective

Kevin C. Oeffinger, MD

Session SV104

**Nursing Perspective** 

Catherine Hydzik, RN, MS, AOCN

Session SV105

Pediatric Oncology Perspective

Les L. Robison, MD

#### Focus on Melanoma

Moderator: Frank G. Haluska, MD, PhD

1:00 pm - 4:00 pm

Skin cancer is the third most common human malignancy and its global incidence is rising at an alarming rate, with basal cell carcinoma, squamous cell carcinoma and melanoma being the most common forms. There are an estimated 2-3 million cases of skin cancer across the world each year, and although melanoma only accounts for about 132,000 of these (World Health Organization), it is the most dangerous form, accounting for most skin cancer deaths.

#### Who should attend:

- Oncologists
- Dermatologists
- Nurses
- Physician Assistants

Session M101

Staging and Prognostic Factors

Charles M. Balch, MD

Session M102

**Surgical Update** 

Merrick I. Ross, MD

Session M103

**Adjuvant Therapy** 

David H. Lawson, MD

Session M104

Systemic Therapy 1: Immunotherapy

Paul B. Chapman, MD

Session M105

Systemic Therapy 2: Targeted Therapy

Frank G. Haluska, MD, PhD

## Conference Sessions



### FRIDAY SEPTEMBER 7th

#### **Hematologic Malignancies**

Leukemia

Moderator: Martin S. Tallman, MD

8:00 am - 8:30 am

Session H201

AML: Integrating New Strategies in Induction and Post Remission Therapy

Charles A. Schiffer, MD

8:35 am - 9:00 am

Session H202

APL: Curative Therapies in 2007

Martin S. Tallman, MD

9:05 am - 9:30 am

Session H203

ALL: Risk-Adapted Induction and Post Remission Therapy

Dan Douer, MD

9:35 am - 10:00 am

Session H204

CLL: New Approaches for High-Risk Patients

William G. Wierda, MD, PhD

10:05 am - 10:30 am

Session H205

CML: Second Generation Tyrosine Kinase Inhibitors

Michael J. Mauro, MD

2:05pm - 3:00 pm

Session H206

MPD: New Molecular Insights and Therapies in an Old Disease

Avalew Tefferi, MD

#### **Gastrointestinal Malignancies**

#### **Colon Cancer**

Moderator: Alan P. Venook, MD

8:00 am - 8:30 am

Session GI201

Is There an Order to Therapy?

Axel Grothey, MD

8:35 am - 9:00 am

Session GI202

Current Standards and Research Questions in Rectal Cancer

Joel E. Tepper, MD

9:05 am - 9:30 am

Session GI203

Optimal Use of Biologics in Colon Cancer

Emily K. Bergsland, MD

9:35 am - 10:00 am

Session GI204

Management of Metastatic Colon Cancer

Metastatic to the Liver

Alan P. Venook, MD

10:05 am - 10:30 am

Session GI205

Surgery for Stage IV Disease

Robert S. Warren, MD

2:05pm - 2:30 pm

Session GI206

Adjuvant Therapy of Colon Cancer

Mary F. Mulcahy, MD

2:35pm - 3:00 pm

Session GI207

How Does One Counsel Cost of Rx?

#### **Supportive Care**

Moderator: Michael J. Fisch, MD, MPH

8:00 am - 9:00 am

Session SC201

**Negotiating Goals of Care** 

Anthony L. Back, MD Megan Cole, MA

9:05 am - 9:30 am

Session SC202

RO Managing Dysphagia and Mucositis in Patients Receiving Radiotherapy

David I. Rosenthal, MD

Davia I. Hoodiitiiai, iiii

9:35 am – 10:00 am

Session SC203

Prevention of Thrombosis in Cancer

Patients – What is the Emerging Story?

Rodger L. Bick, MD

10:05 am - 10:30 am

Session SC204

Personalized Medicine Applied to Preventing or Managing Toxicity Due to

Chemotherapy

Victor T. Chang, MD

2:05pm - 2:30 pm

Session SC205

Addressing Psychological Distress in Cancer Outpatients-Individual and

**Programmatic Approaches** 

Caroline Carney-Doebbeling, MD, MSc

2:35pm - 3:00 pm

Session SC206

Elegant Strategies in Opioid Prescribing

for Cancer Patients

Janet L. Abrahm, MD

### Head and Neck Cancer

Moderator: Everett E. Vokes, MD

8:00 am - 8:30 am

Session HN201

Role of Induction Chemotherapy

8:35 am - 9:00 am

Session HN202

RO Role of Concomitant

Chemoradiotherapy

Everett E. Vokes, MD

9:05 am - 9:30 am

Session HN203

Integration of Targeted Therapies into Combined Modality Therapy

Paul M. Harari, MD

9:35 am - 10:00 am

Session HN204

RO Novel Approaches to XRT

William G. Wierda, MD, PhD

10:05 am - 10:30 am

Session HN205

Standard and Investigational Agents in Systemic Therapy for Recurrent Disease

A. Dimitrios Colevas, MD

#### **Thryoid**

2:05pm - 2:30 pm

Session HN206

Molecular Biology of HNC

Ezra EW Cohen, MD

2:35pm - 3:00 pm

Session HN207

Malignancies of the Thyroid

Rebecca L. Brown, MD

### SATURDAY SEPTEMBER 8th

#### **Hematologic Malignancies**

#### Lymphoma

Moderator: Sandra J. Horning, MD

8:00 am - 8:30 am

Session H301

Follicular Lymphoma — Choosing the Right

Treatment for the Patient

David G. Maloney, MD, PhD

8:35 am - 9:00 am

Session H302

How I Treat Diffuse Large Cell Lymphoma?

9:05 am - 9:30 am

Session H303

Lymphoma Pathology for Clinicians – Getting the Most Out of the Pathology

Report and When to Ask for More

Randy D. Gascoyne, BSc, MD

9:35 am - 10:00 am

Session H304

Mantle Cell Lymphoma – Treatment and Retreatment Strategies

Bradley S. Kahl, MD

#### Myeloma

Moderator: Kenneth C. Anderson, MD

1:35pm - 2:00 pm

Session H305

Conventional Therapy vs. Transplant

William I. Bensinger, MD

2:05pm - 2:30 pm

Session H306

**Novel Therapies** 

Kenneth C. Anderson, MD

#### Lymphoma

4:35pm - 5:00 pm

Session H307

Extranodal Non-Hodgkin's Lymphomas – Pearls for Practice

5:05pm - 5:30 pm

Session H308

RO The Role of Radiation Therapy in Lymphoma Treatment

Richard T. Hoppe, MD

#### **Gynecologic Malignancies**

#### **Ovarian Cancer**

Moderator: John T. Soper, MD

8:00 am - 8:30 am

Session GY301

CA-125 – How Should It Be Used?

Jonathan S. Berek, MD, MMS

8:35 am - 9:00 am

Session GY302

Integration Surgery into the Management of Ovarian Cancer: How Do We Pick and Choose Patients?

David G. Mutch, MD

9:05 am - 9:30 am

Session GY303

Chemotherapy Overview

Jonathan S. Berek, MD, MMS

9:35 am - 10:00 am

Session GY304

**Ovarian Maintenance Therapy** 

Pro: John T. Soper, MD

Con:

#### **Cervical Cancer**

Moderator: John T. Soper. MD

1:35pm - 2:00 pm

Session GY305

**Multimodality Therapy** 

Bradley J. Monk, MD

2:05pm - 2:30 pm

Session GY306

**Symptom Management** 

David G. Mutch, MD

4:35pm - 5:00 pm

Session GY307

Borderline and Non Epithelial Ovarian Tumors

5:05pm - 5:30 pm

Session GY308

**Gestational Trophoblastic Disease** 

John T. Soper, MD

#### SATURDAY SEPTEMBER 8th

#### **Urologic Malignancies**

#### **Bladder Cancer**

Moderator: Dean F. Bajorin, MD

8:00 am - 9:00 am

Session U301

**Invasive Bladder Cancer:** 

What's the Appropriate Approach?

Bladder Sparing:

Howard M. Sandler, MD

Surgical Perspective:

Michael O. Koch, MD

#### **Testicular Cancer**

Moderator: Patrick J. Loehrer, Sr., MD

9:05 am - 9:30 am

Session U302

Early Stage Disease: Comments and

Controversies

Patrick J. Loehrer, Sr., MD

9:35 am - 10:00 am

Session U303

Advanced Testicular Cancer - Update

Dean F. Bajorin, MD

#### **Renal Cell Cancer**

1:35pm - 2:00 pm

Session U304

Systemic Therapy: Who, What,

When & How

2:05pm - 2:30 pm

Session U305

Basic Biology for Clinicians

Robert A. Figlin, MD

4:35pm - 5:00 pm

Session U306

Cytoreductive Radical Nephrectomy in Metastatic Renal Cell Carcinoma:

Standard of Care?

Pro: Peter R. Carroll. MD Con: Robert A. Figlin, MD

#### **Gastrointestinal Malignancies**

#### **Pancreatic Cancer**

8:00 am - 8:30 am

Session GI301

Why is Pancreatic Cancer So Nasty?

Nabeel Bardeesy, PhD

8:35 am - 9:00 am

Session GI302

Systemic Therapy for Pancreatic Cancer

Philip A. Philip, MD, PhD

9:05 am - 10:00 am

Session GI303

Whither Whipple

Douglas B. Evans, MD

1:35pm - 2:00 pm

Session GI304

**RO** Treatment of Locally Advanced

Pancreatic Cancer with Chemoradiation

Edgar Ben-Josef, MD

2:05pm - 2:30 pm

Session GI305

RO Is There a Role for Radiation

in Local Advanced Pancreatic

Cancer? Debate

Patrick J. Loehrer, Sr., MD

4:35pm - 5:00 pm

Session GI306

Islet Cell/Neuro

Herbert Chen, MD

5:05pm - 5:30 pm

Session GI307

Supportive and Palliative Management

in Pancreatic Cancer

Michael J. Fisch, MD, MPH

#### SUNDAY SEPTEMBER 9th

#### **Urologic Malignancies**

#### **Prostrate Cancer**

Moderators: Theodore L. DeWeese, MD/ Otis W. Brawley, MD

8:00 am - 9:00 am

Session U401

Early vs. Delayed Androgen Suppression for Rising PSA Post Definitive Therapy

Con: Nancy A. Dawson, MD

9:05 am - 9:30 am

Session U402

Is PSA Passe? (and other Markers for PC)

Otis W. Brawlev. MD

9:35 am - 10:00 am

Session U403

**Novel Molecular Targets** 

Samuel R. Denmeade, MD

10:05 am - 10:30 am

Session U404

Supportive Care Issues in Prostate Cancer

Timothy Gilligan, MD

10:35 am - 11:00 am

Session U405

Prostate: Beyond Hormonal Therapy

William L. Dahut. MD

11:05 am - 11:30 am

Session U406

**RO** Robotic Prostatectomy

Timothy G. Wilson, MD


11:35 am - 12:00 pm

Session U407

RO IMRT

Michael R. Kuettel, MD, PhD

This session is sponsored by the American College of Radiation Oncology



#### **Breast Cancer**

Moderators: Hyman B. Muss, MD/ George W. Sledge, Jr., MD

8:00 am - 8:50 am

Session B401

All Post Menopausal Women with Hormone Receptor Positive Early Stage Breast Cancer Should be Treated Initially with Aromatase Inhibitor

Pro: Aman U. Buzdar, MD Con: Harold J. Burstein, MD

8:50 am - 9:40 am

Session B402

All Patients With HER2+ Early Breast Cancer Should Have Trastuzumab as Part of Their Adjuvant Treatment

Pro: Edith A. Perez, MD Con: Peter Ravdin, MD, PhD

9:40 am - 10:30 am

Session B403

All Patients with Metastatic Breast Cancer Should be Treated with Combination Chemotherapy as Opposed to Sequential Single Agents

Pro: William J. Gradishar, MD Con: Hyman B. Muss, MD

10:35 am - 1100 am

Session B404

**Novel Aspects of HER2-Targeted Therapy** 

Mark D. Pegram, MD

11:05 am - 11:30 am

Session B405

Therapeutic Individualization in Breast Cancer

George W. Sledge, Jr., MD

11:35 am - 12:00 pm

Session B406

Antiangiogenic Therapy in Breast Cancer

Hope S. Rugo, MD

#### **Lung Cancer**

Moderator: David H. Johnson, MD

8:00 am - 8:30 am

Session L401

Role of Post-Operative Adjuvant Chemotherapy in Stage I NSCLC

David H. Johnson, MD

8:35 am - 9:00 am

Session L402

Optimal Second-Line Therapy for Recurrent NSCLC

H. Jack West, MD

9:05 am - 9:30 am

Session L403

Optimal Management of Stage IIIA-N2 NSCLC

9:35 am - 10:00 am

Session L404

Surgery for N2(2) NSCLC; Post Neoadjuvant Chemotherapy

Joe B. Putnam, MD

10:05 am - 10:30 am

Session L405

Selecting Appropriate Patients for

**EGFR TKI Therapy** 

Gregory J. Riely, MD, PhD

10:35 am - 11:00 am

Session L406

Managing Elderly Patients with NSCLC

Corey J. Langer, MD

11:05 am - 11:30 am

Session L407

Antiangiogenic Agents in NSCLC: Standard of Care or Care Seeking a

Standard?

11:35 am - 12:00 pm

Session L408

Early Detection: The Role of CT Scan Screening for Lung Cancer – The Good,

The Bad, and the Ugly Michael K. Gould, MD

#### Sarcoma

Moderator: Laurence H. Baker, DO

8:00 am - 8:30 am

Session S401

Survivorship Issues

Laurence H. Baker, DO

8:35 am - 9:00 am

Session S402

Surgery and Soft Tissue Sarcoma

J. Sybil Bierman, MD

9:05 am - 9:30 am

Session S403

Title TBD

9:35 am - 10:00 am

Session S404

Title TBD

RO Radiology Focused Session

## Conference Location

#### ONLY IN SAN FRANCISCO

Always at the top of everyone's list of favorite travel destinations, San Francisco offers a remarkable number of cultural attractions and world famous landmarks set against a background of extraordinary natural beauty.

Located in the heart of the city, Union Square is bordered by Geary, Powell, Post and Stockton Streets and is bordered by fashionable stores, major retailers and hotels, and is one the City's major shopping areas. The adjoining streets are lined with restaurants, theaters, boutiques, galleries, shops and services. Adjacent Maiden Lane is an historic 2-block alley, extending off Stockton to Grant, lined with upscale shops, cafés and salons. Architectural buffs will be particularly interested in the Frank Lloyd Wright Building, located at 140 Maiden Lane, built in 1948, the city's only Wright-designed structure.

> The Financial District and Chinatown are within walking distance and the criss-cross of public transportation will take you anywhere in the city. Cable cars run from Market Street to Fisherman's Wharf.



#### HOTEL INFORMATION

A block of rooms is being held at the Hilton San Francisco.

The Hilton San Francisco contributes to the city's reputation as a culinary mecca with their fine selection of restaurants and bars: Cityscape, The Café, Intermezzo, Lobby Bar, and Kiku of Tokyo. Don't miss Cityscape Bar & Restaurant's one-of-a-kind view of San Francisco, nightly dancing, and it's extensive selection of California wines.

After a day of meetings, quests can relax in the hotel's full service spa. Spa Fusion and Health club is a sanctuary of relaxation and renewal - an urban retreat blending Eastern healing traditions with Western discoveries, Spa Fusion offers an essential union of luxurious therapies infused with the uniqueness of San Francisco.

We are fortunate to have obtained especially low rates at the hotel starting at \$189 per night, single/double (plus tax).

#### HOTEL RESERVATIONS

This block of rooms will be held for the Oncology Congress until August 15, 2007. After that time, reservations will be made on a space available basis.

To ensure the group rate, reservations must be made through the Oncology Congress Travel Desk:

Online: www.oncologycongress.com/travel

**Phone:** 800-388-8002 within the U.S.

1-312-527-7300 for international callers 7:00 am - 6:00 pm CST, Monday - Friday

oncologycongress@ttgonline.com Email:

1-312-329-9513 Fax:

Mail: Oncology Congress c/o Travel Technology Group,

110 West Hubbard, Chicago, IL 60610

Hilton San Francisco, 333 O'Farrell Street, San Francisco, CA 94102

## Our Partners (as of 5/7/07)

#### INSTITUTION PARTNERS







#### SOCIETY PARTNERS





**PUBLICATIONS PARTNERS** 





#### MEDIA PARTNERS

























## Registration Form

Prefix First Name	Last Name	
Suffix/Degree Title		Third Annual ONCOLOGY
Affiliation/Institution		CONGRESS
Anniation/institution		September 6-9, 2007 • San Francisco
Address 1		TO REGISTER:
Address 2		ONLINE: www.oncologycongress.com/attender
City	State ZIP/Postal Code	FAX FORM TO: 708-344-4444
Country	Telephone (do not include international dialing codes)	MAIL THIS FORM AND PAYMENT TO: Oncology Congress
please see our privacy statement at www.oncologyco	Email  about the Oncology Congress and other organizations in your field. If you prefer not to receive further information, angress.com or call our privacy administrator at 888-306-2344 or 203-840-5810.  Your answers will help us to build an event around your needs and interests.	P.O. Box 571 Brookfield, IL 60513-0571 Questions? Call 888-799-2995
1. What is your specialty?  A.	2. Type of practice A. O Community/Private B. O Hospital C. O Academic D. Other	AV. O Reimbursement AW. O Sarcoma AX. O Supportive Care AY. O Survivorship AZ. O Targeted Therapies BA. O Urologic Malignancies BB. O Other  4. Number of physicians in your practice? A. O Solo B. O 2-5 C. O 6-10 D. O >10

	Thru 6/29/0	
Pre-Conference Program (not included in full conference packages)	0/20/0	0,20,01
O Thursday	\$175	\$175
Conference – Includes 3 days of conference, continental breakfast, lunch*, and conference materials		
Oncologist/Clinician	\$795	\$995
O Nurse/Physician Assistant/Pharmacist/Social Worker	\$395	+
O Fellow/Resident	\$295	+
O Industry	\$1095	\$1195
One Day Pass – Includes continental breakfast, lunch*, and conference materials for the day of your choice (not available for industry)		
O Friday	\$395	\$495
O Saturday	\$395	+
O Sunday	\$395	\$495
Dinner Reception # of tickets		
○ Saturday	\$99	\$99
Guest Pass	\$100	\$100
O Guest Name		
Syllabus – Available for purchase to non-attendees		
(included for all attendees)	\$150	\$150
○ Print ○ CD-ROM		
*Lunch not available on Sunday.		
Program ends at 12pm.	al \$	\$

METHOD	OF PAYMENT
	l is check # payable to Reed Medical Education ny (circle one) VISA MASTERCARD AMEX
Account Nur	-      -      -      nber
	ate (month/year)
Signature	
Cardholder I	Name (please print)

GUEST PASS: Reed Medical Education adheres to PHRMA guidelines regarding interaction with healthcare professionals, therefore guest passes may be purchased allowing guests of registrants to have access to the exhibit hall and non-CME group meal functions only.

CANCELLATION POLICY: Cancellations received in writing on or before August 20, 2007 will be refunded less a \$100 service fee. No refunds will be made for cancellations received after this date or "no shows." Substitutions are welcome.

SPECIAL NEEDS: We encourage participation by all individuals. If you have a disability, advanced notification of any special needs will help us better serve you. Please contact Briget Stronge at least 2 weeks in advance at 203-840-5548 or bstronge@ReedMedEd.com.

Produced and managed by:

